Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04825288
PHASE1/PHASE2

XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer

Sponsor: XBiotech, Inc.

View on ClinicalTrials.gov

Summary

This trial will include 2 portions (phase 1 and phase 2). The first portion will be a Phase I, open label, dose escalation study to establish the maximum tolerated dose (MTD) of XB2001 as measured by Dose-Limiting Toxicity (DLT), in combination with ONIVYDE + LV + 5-FU chemotherapy regimen in patients with advanced pancreatic cancer and to determine the recommended dose for the subsequent Phase 2 study. The phase 2 portion will be implemented with the maximum established tolerated dose (MTD) of XB2001. The target enrollment in the phase 2 portion is 60 patients which will be randomized on a 1:1 basis to XB2001 plus ONIVYDE + LV + 5-FU (Arm 1) or placebo plus ONIVYDE + LV + 5-FU (Arm 2).

Official title: A Phase I/II Randomized, Double-blind, Placebo-controlled Trial (1-BETTER) Examining XB2001 (Anti-IL-1⍺ True Human Antibody) in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

76

Start Date

2021-05-27

Completion Date

2025-06-10

Last Updated

2025-02-28

Healthy Volunteers

No

Interventions

BIOLOGICAL

XB2001 or Placebo

XB2001 is a True Human monoclonal antibody that blocks the biological activity of IL-1α with a high degree of affinity and specificity. IL-1⍺ is a key mediator of inflammatory responses and is implicated in the pathophysiology of various diseases, including cancer, cardiovascular and rheumatologic diseases. Ample evidence supports targeting IL-1⍺ to block pathological inflammatory processes associated with many diseases.

Locations (28)

Arizona Oncology Associates

Tucson, Arizona, United States

Disney Family Cancer Center at Providence St. Joseph Medical Center

Burbank, California, United States

TOI Clinical Research

Cerritos, California, United States

Providence St. Joseph Heritage - Fullerton, CA

Fullerton, California, United States

Hoag Memorial Hospital Presbyterian

Newport Beach, California, United States

Grand Valley Oncology

Grand Junction, Colorado, United States

Sarah Cannon - Florida Cancer Specialists

Lake Mary, Florida, United States

Mt. Sinai Comprehensive Cancer Center

Miami Beach, Florida, United States

Sarasota Memorial Hospital

Sarasota, Florida, United States

Goshen Center for Cancer Care

Goshen, Indiana, United States

Alliance for Multispecialty Research, LLC

Merriam, Kansas, United States

Ochsner Clinic Foundation

New Orleans, Louisiana, United States

Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, United States

Revive Research - Farmington Hills

Farmington Hills, Michigan, United States

Revive Research - Sterling Heights

Sterling Heights, Michigan, United States

St. Vincent Frontier Cancer Center

Billings, Montana, United States

Summit Medical Group

Florham Park, New Jersey, United States

Stony Brook Cancer Center

Stony Brook, New York, United States

Montefiore Einstein Medical Center

The Bronx, New York, United States

Providence Portland

Portland, Oregon, United States

UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, United States

University of Tennessee Medical Center Cancer Institute

Knoxville, Tennessee, United States

Sarah Cannon - Tennessee Oncology

Nashville, Tennessee, United States

Vanderbilt University

Nashville, Tennessee, United States

Mary Crowley Cancer Research

Dallas, Texas, United States

Community Cancer Trials of Utah

Ogden, Utah, United States

Virginia Cancer Specialists

Fairfax, Virginia, United States

Bon Secours St. Francis Cancer Center

Midlothian, Virginia, United States